RATIONALE: 3, 4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a popular drug of abuse known to result in depletions of the serotonin (5-HT) system. A number of studies have reported that ecstasy users differ from controls on a variety of measures of cognitive function. However, the literature is not consistent and many negative findings were also reported. One reason for such inconsistency might be interindividual variance in vulnerability to the deleterious effects of ecstasy due to a number of factors, both genetic and environmental. OBJECTIVES: To investigate the hypothesis that carriers of the s allele at the 5-HT transporter gene-linked polymorphic region (5-HTTLPR), which was associated with reduced serotonergic neurotransmission relative to the l allele, would be most vulnerable to the effects of ecstasy on cognitive function. METHODS: We assessed memory, decision-making, and executive function in ecstasy users and controls, stratifying by genotype at the 5-HTTLPR. RESULTS: We observed that the 5-HTTLPR genotype groups differed on a number of measures in both the ecstasy users and the controls. While performing a risky decision-making task, ss and ls controls attended to differences in the probability of winning chosen gambles to a greater extent than the ll controls. However, this difference was dramatically attenuated in the ss ecstasy users. Furthermore, independent of ecstasy use, volunteers of the ss genotype outperformed the ll genotype on a visual planning task. CONCLUSIONS: The results are consistent with the hypothesis that cognitive impairment in ecstasy users may depend on genetic variation at the 5-HTTLPR.
RATIONALE: 3, 4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a popular drug of abuse known to result in depletions of the serotonin (5-HT) system. A number of studies have reported that ecstasy users differ from controls on a variety of measures of cognitive function. However, the literature is not consistent and many negative findings were also reported. One reason for such inconsistency might be interindividual variance in vulnerability to the deleterious effects of ecstasy due to a number of factors, both genetic and environmental. OBJECTIVES: To investigate the hypothesis that carriers of the s allele at the 5-HT transporter gene-linked polymorphic region (5-HTTLPR), which was associated with reduced serotonergic neurotransmission relative to the l allele, would be most vulnerable to the effects of ecstasy on cognitive function. METHODS: We assessed memory, decision-making, and executive function in ecstasy users and controls, stratifying by genotype at the 5-HTTLPR. RESULTS: We observed that the 5-HTTLPR genotype groups differed on a number of measures in both the ecstasy users and the controls. While performing a risky decision-making task, ss and ls controls attended to differences in the probability of winning chosen gambles to a greater extent than the ll controls. However, this difference was dramatically attenuated in the ss ecstasy users. Furthermore, independent of ecstasy use, volunteers of the ss genotype outperformed the ll genotype on a visual planning task. CONCLUSIONS: The results are consistent with the hypothesis that cognitive impairment in ecstasy users may depend on genetic variation at the 5-HTTLPR.
Authors: J S Rubinsztein; R D Rogers; W J Riedel; M A Mehta; T W Robbins; B J Sahakian Journal: Psychopharmacology (Berl) Date: 2001-03 Impact factor: 4.530
Authors: Una D McCann; Zsolt Szabo; Esen Seckin; Peter Rosenblatt; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte Journal: Neuropsychopharmacology Date: 2005-09 Impact factor: 7.853
Authors: J A Schmitt; B L Jorissen; S Sobczak; M P van Boxtel; E Hogervorst; N E Deutz; W J Riedel Journal: J Psychopharmacol Date: 2000-03 Impact factor: 4.153
Authors: Ahmad R Hariri; Emily M Drabant; Karen E Munoz; Bhaskar S Kolachana; Venkata S Mattay; Michael F Egan; Daniel R Weinberger Journal: Arch Gen Psychiatry Date: 2005-02
Authors: Sean P David; Naga Venkatesha Murthy; Eugenii A Rabiner; Marcus R Munafó; Elaine C Johnstone; Robyn Jacob; Robert T Walton; Paul M Grasby Journal: J Neurosci Date: 2005-03-09 Impact factor: 6.167
Authors: Gwenn S Smith; Francis E Lotrich; Anil K Malhotra; Annette T Lee; Yilong Ma; Elisse Kramer; Peter K Gregersen; David Eidelberg; Bruce G Pollock Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Bhaskar Kolachana; Francesco Fera; David Goldman; Michael F Egan; Daniel R Weinberger Journal: Science Date: 2002-07-19 Impact factor: 47.728
Authors: Bryan Maloney; Balmiki Ray; Elizabeth P Hayden; John I Nurnberger; Debomoy K Lahiri Journal: Psychiatr Genet Date: 2009-04 Impact factor: 2.458
Authors: James J Li; Tammy A Chung; Michael M Vanyukov; D Scott Wood; Robert Ferrell; Duncan B Clark Journal: J Int Neuropsychol Soc Date: 2014-12-15 Impact factor: 2.892
Authors: H P Jedema; P J Gianaros; P J Greer; D D Kerr; S Liu; J D Higley; S J Suomi; A S Olsen; J N Porter; B J Lopresti; A R Hariri; C W Bradberry Journal: Mol Psychiatry Date: 2009-09-01 Impact factor: 15.992